Royal Bank Of Canada Avadel Pharmaceuticals PLC Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Nov 05, 2024	BUY	$12.55 - $17.22 $1.54 Million - $2.11 Million	122,565 New	122,565 $2.07 Million
Q1 2024 May 15, 2024	BUY	$12.55 - $17.22 $1.49 Million - $2.05 Million	118,990 Added 3328.39%	122,565 $2.07 Million
Q3 2023 Nov 14, 2023	SELL	$10.3 - $15.99 $91,515 - $142,071	-8,885 Reduced 71.31%	3,575 $36,000
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $105,660 - $205,340	12,460 New	12,460 $205,000
Q2 2022 Aug 15, 2022	SELL	$1.07 - $6.95 $499 - $3,245	-467 Reduced 70.01%	200 $0
Q1 2022 May 16, 2022	SELL	$5.46 - $8.29 $420 - $638	-77 Reduced 10.35%	667 $4,000
Q4 2021 Feb 14, 2022	SELL	$7.34 - $11.18 $1,423 - $2,168	-194 Reduced 20.68%	744 $7,000
Q3 2021 Nov 15, 2021	BUY	$6.49 - $9.91 $3,355 - $5,123	517 Added 122.8%	938 $10,000
Q2 2021 Aug 16, 2021	BUY	$6.73 - $9.05 $2,833 - $3,810	421 New	421 $2,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $662M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.